Please login to the form below

SGLT2 inhibitor

This page shows the latest SGLT2 inhibitor news and features for those working in and with pharma, biotech and healthcare.

J&J’s Invokana aces diabetic kidney disease trial, setting up filings

The SGLT2 inhibitor could be the first new drug in 15 years that slows kidney damage development. ... Johnson &Johnson’s SGLT2 inhibitor Invokana worked so well in a trial involving diabetics with chronic kidney disease that the study has been halted

Latest news

J&J says real-world data finds no amputation risk for Invokana

A year ago, regulators slapped warnings to the labelling for Johnson &Johnson’s diabetes drug Invokana, setting it at a disadvantage against rival drugs in the SGLT2 inhibitor class, but now ... results show that the “overall benefit-risk profile of
PMCPA takes AZ to task over asthma drug press release

body. The source of GSK’s anger was a PR put out by AZ after interleukin-5 inhibitor Fasenra (benralizumab) was recommended for approval by the EMA’s Committee for Medicinal ... company in Amsterdam last November relating to SGLT2 inhibitor diabetes
FDA starts review of Sanofi’s oral type 1 diabetes drug

The drug is a dual inhibitor of SGLT1 and SGLT2 and is thought to work by reducing glucose absorption in the gastrointestinal tract and glucose reabsorption by the kidneys, as well ... The SGLT2-selective drugs are approved to date only for type 2
FDA’s year-end approvals take annual tally to 46

Merck and Pfizer picked up an FDA approval for SGLT2 inhibitor Steglatro (ertugliflozin) and combinations Steglujan (ertugliflozin and sitagliptin) and Segluromet (ertugliflozin and metformin) for use in adults with type 2 ... Steglatro is the
J&J seeks US OK to add CV claim to Invokana label

The filing is based on the results of the CANVAS trial, which showed that its SGLT2 inhibitor Invokana (canagliflozin) was able to reduce the combined risk of cardiovascular death, myocardial infarction ... If the FDA approves the label, Invokana could

More from news
Approximately 1 fully matching, plus 62 partially matching documents found.

Latest Intelligence

Medius Deal Watch table for March 2015

Company acquisition. Marketed BTK inhibitor for haematological cancers pipeline incl. 3 products in clinic. ... 165. Brighthaven Ventures/ Islet Sciences. Licence and collaboration. Phase 2b SGLT2 inhibitor remogliflozin for treatment of diabetes.
Interview: Christopher Boulton, AstraZeneca

Between them, the companies developed the DPP-4 inhibitor Onglyza (saxagliptin), the saxagliptin/metformin combination product Kombiglyze and the SGLT2 inhibitor Forxiga (dapagliflozin), all of which have received approvals in various ... The deal gives
Pharma deals during April 2013

The partnership is to co-develop and commercialise Pfizer's phase III ready oral sodium glucose co-transporter (SGLT2) inhibitor ertugliflozin for the treatment of type 2 diabetes, both as a ... Clearly the pressure is on, the announcement coming only a

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

Pfizer appoints diabetes expert Morris Birnbaum

Pfizer's interests in the area include a collaboration with Merck &Co on the sodium glucose co-transporter (SGLT2) inhibitor ertugliflozin to treat diabetes.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Healthcare PR Director: £100, 000 – £120, 000 benefits

Editorial Director – Medical Education (MedComms): Neg

Home based, Principal Medical Writer, Medical Communications: Excellent package

Scientific Communications Director - Oncology – In House Pharma ...: Neg

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Account Director, Medical Communications: C£50 – 65, 000 benefits and bonus

Client Services Director – Healthcare Advertising - London: Neg

Strategic Planner, Healthcare Advertising: £47, 000 – £53, 000

Business Unit Head, Medical Communications, London: Excellent package

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Home based, Chief Medical Writer, Medical Communications: Excellent package

Home based, Editorial Team Leader, Medical Communications: Excellent package

Client Services Director - Med Comms: Great salary and bebefits

Home based, Senior Medical Writer, Medical Communications: Excellent package

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Senior Account Manager: Competitive salary commensurate with experience

Delivery Manager/ Head of Delivery – Executive Search: Neg

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Account Manager: £40, 000 - £45, 000 benefits

Subscribe to our email news alerts

PMHub

Add my company

Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

Developing advocacy in the pharmaceutical industry.: The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?: Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....